circRNA Dysfunction Restoration Therapy

Migration, Crosslink

📖

circRNA Dysfunction Restoration Therapy

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-circrna-dysfunction-restorati

📖 Wiki Page

idea1625 wordssynced 2026-04-02

Overview

flowchart TD circRNA_Dysfunction_Restoratio["circRNA Dysfunction Restoration Therapy"] circRNA_Dysfunction_Restoratio["novel"] circRNA_Dysfunction_Restoratio -->|"related to"| circRNA_Dysfunction_Restoratio style circRNA_Dysfunction_Restoratio fill:#81c784,stroke:#333,color:#000 circRNA_Dysfunction_Restoratio["approach"] circRNA_Dysfunction_Restoratio -->|"related to"| circRNA_Dysfunction_Restoratio style circRNA_Dysfunction_Restoratio fill:#81c784,stroke:#333,color:#000 circRNA_Dysfunction_Restoratio["aims"] circRNA_Dysfunction_Restoratio -->|"related to"| circRNA_Dysfunction_Restoratio style circRNA_Dysfunction_Restoratio fill:#81c784,stroke:#333,color:#000 style circRNA_Dysfunction_Restoratio fill:#4fc3f7,stroke:#333,color:#000

circRNA Dysfunction Restoration is a novel therapeutic approach that aims to restore levels of neuroprotective circular RNAs (circRNAs) in the aging and neurodegenerative brain. CircRNAs are covalently closed, stable non-coding RNAs that function primarily as microRNA "sponges" and regulators of gene expression. Several neuroprotective circRNAs decline with age and in Alzheimer's disease, Parkinson's disease, and ALS, contributing to synaptic dysfunction and neuronal vulnerability. This therapy uses antisense oligonucleotides (ASOs) or CRISPR-based approaches to restore these protective circRNAs. [@hanan2022] [@kumar2023]

...

Overview

Mermaid diagram (expand to render)

circRNA Dysfunction Restoration is a novel therapeutic approach that aims to restore levels of neuroprotective circular RNAs (circRNAs) in the aging and neurodegenerative brain. CircRNAs are covalently closed, stable non-coding RNAs that function primarily as microRNA "sponges" and regulators of gene expression. Several neuroprotective circRNAs decline with age and in Alzheimer's disease, Parkinson's disease, and ALS, contributing to synaptic dysfunction and neuronal vulnerability. This therapy uses antisense oligonucleotides (ASOs) or CRISPR-based approaches to restore these protective circRNAs. [@hanan2022] [@kumar2023]

| Attribute | Value |
|---|---|
| Therapy Name | circRNA Dysfunction Restoration |
| Category | Novel target |
| Target Diseases | Alzheimer's Disease, Parkinson's Disease, ALS |
| Total Score | 71/100 |
| AD Score | 8/10 |
| PD Score | 8/10 |
| ALS Score | 6/10 |
| FTD Score | 6/10 |
| Aging Score | 7/10 |

Mechanistic Rationale

The circRNA Biology

Circular RNAs (circRNAs) are formed through back-splicing, a process where a downstream 5' splice site connects to an upstream 3' splice site, creating a covalently closed loop structure. This structure makes circRNAs highly stable, resistant to exonuclease degradation, and long-lived in cells—properties that make them attractive as therapeutic targets. [@kristensen2022]

Key neuroprotective circRNAs include:

CDR1as (circRNA-7 / ciRS-7): The most well-characterized circRNA, CDR1as acts as a potent sponge for miR-7, a microRNA that regulates many neuronal genes. CDR1as contains over 70 miR-7 binding sites, sequestering miR-7 and preventing it from repressing target mRNAs involved in synaptic function, neuroprotection, and protein quality control. [@hansen2013]

circSAMD4A: A circRNA that is downregulated in AD brains and regulates synaptic plasticity through miR-138 sequestration. [@dube2019]

circH1PRX: A circular RNA that declines in AD and regulates genes involved in [amyloid-beta](/proteins/amyloid-beta) metabolism. [@zhang2021]

circTLK2: Implicated in PD pathogenesis; regulates neuronal survival through miR-106b binding. [@jin2022]

circSCFD2: Involved in axonal guidance and synaptic function; declines in multiple neurodegenerative conditions. [@ahmad2023]

Why circRNA Restoration?

The "circRNA dysfunction" hypothesis proposes that:

Age-related decline: CircRNA levels naturally decline with age due to reduced back-splicing efficiency and increased degradation

Disease-specific loss: Neurodegenerative diseases accelerate circRNA loss through transcriptional dysregulation

Loss-of-function consequences: Reduced circRNA sponge activity leads to increased microRNA activity, which in turn represses neuroprotective genes

Aggregation susceptibility: Some circRNAs normally bind to and sequester aggregation-prone proteins; their loss may increase aggregation risk

Restoring circRNA levels could:

Re-sequester dysregulated microRNAs
Restore expression of microRNA-targeted neuroprotective genes
Reduce synaptic dysfunction
Potentially interfere with protein aggregation through direct protein binding

Therapeutic Approaches

Approach 1: ASO-Mediated circRNA Upregulation

Design antisense oligonucleotides that bind to the flanking introns of circRNA host genes
The ASO blocks the formation of the linear mRNA splice, shifting splicing toward back-splicing
This increases circRNA production without altering gene transcription
Similar to the nusinersen approach for spinal muscular atrophy [@rigo2014]

Approach 2: circRNA Mimetics (Direct Administration)

Synthesize exogenous circRNA molecules that mimic endogenous neuroprotective circRNAs
Deliver via lipid nanoparticles (LNPs) or AAV vectors
Bypass the need to modify endogenous splicing
Challenge: achieving proper subcellular localization and functional integration [@wesselhoeft2019]

Approach 3: CRISPR Activation

Use dCas9 fused to transcriptional activators (e.g., VP64, SunTag) to enhance back-splicing
Guide RNAs target the circularization introns
Permanent modification for long-term therapy
Requires CNS delivery (AAV, AAV9, or engineered variants) [@ruan2021]

Target Selection Priority

| CircRNA | Disease | Primary Target | Priority |
|---|---|---|---|
| CDR1as | AD, PD | miR-7 sequestration | Highest |
| circSAMD4A | AD | Synaptic plasticity | High |
| circTLK2 | PD | Neuronal survival | High |
| circH1PRX | AD | Amyloid metabolism | Medium |

Evidence Base

Preclinical Evidence

CDR1as

CDR1as knockout mice show impaired synaptic transmission and memory deficits [@piwecka2017]
AAV-mediated CDR1as delivery improves cognitive function in 5xFAD mice [@zhang2022]
CDR1as levels are reduced by 40-60% in AD patient brains [@lukiw2018]
miR-7 is upregulated in AD brains and promotes amyloid-beta production [@saugstad2022]

Other circRNAs

circSAMD4A overexpression improves synaptic markers in neuron cultures [@dube2020]
circTLK2 reduction contributes to dopaminergic neuron loss in PD models [@chen2023]
circRNA levels correlate with cognitive performance in aged humans [@grasso2021]

Clinical Evidence

No circRNA-targeted therapies have reached clinical development yet
Several companies (Cardior Pharmaceuticals, Nanosome Therapeutics) are developing circRNA-based cardiovascular therapies, establishing the clinical pathway
Biomarker studies show circRNA levels in blood/CSF may serve as diagnostic or prognostic markers for neurodegeneration [@bhamja2022]

circRNA as Biomarkers

CDR1as can be detected in human CSF and declines in AD [@siegel2021]
Blood circRNA signatures may distinguish AD from PD [@hanan2020]
circRNA profiling may identify patients most likely to respond to restoration therapy

Implementation Roadmap

Preclinical Development (Years 1-4)

Year 1: Target Validation

Confirm circRNA levels in patient-derived [neurons](/entities/neurons) and iPSC models
Validate functional consequences of circRNA loss
Identify optimal circRNA targets

Year 2: Lead Optimization

ASO optimization for CNS delivery
Development of circRNA mimic delivery system
In vivo PK/PD assessment in mouse models

Year 3: Disease Model Testing

Test lead candidates in 5xFAD mice (AD)
Test in [α-synuclein](/proteins/alpha-synuclein) transgenic mice (PD)
Biomarker development for target engagement

Year 4: IND-Enabling Studies

GLP toxicology
Manufacturing development
Regulatory pre-IND meeting

Clinical Development (Years 5-8)

Phase 1 (Year 5): Safety in healthy volunteers Phase 2 (Year 6-7): Efficacy signal in AD or PD Phase 3 (Year 8): Registration trial

Commercial Considerations

Market: Large for AD ($10B+), significant for PD
Competitive landscape: No direct competitors in neurodegeneration
Advantages: Novel mechanism; addresses upstream dysfunction; biomarker-ready
Challenges: CNS delivery; long-term durability; manufacturing complexity for circRNA mimics

Actionable Next Steps

Immediate (0-6 months)

Literature mining: Systematic review of all circRNA expression studies in AD, PD, ALS brain tissue

Target prioritization: Identify the 3-5 most promising circRNA targets based on expression data, functional validation, and druggability

Scientific advisory board: Recruit circRNA experts (Dr. Sebastian Kadener, Dr. Nikolaus Rajewsky)

Near-term (6-18 months)

ASO design: Develop lead ASO candidates targeting back-splicing of priority circRNAs

In vitro validation: Test in patient-derived iPSC neurons

Funding: Submit NIH R01 application for preclinical development

Medium-term (1-3 years)

In vivo efficacy: Test in appropriate mouse models

Delivery optimization: Optimize CNS delivery (AAV9, LNPs)

Partnering: Engage with biotech/pharma partners for co-development

Key Risks

| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Insufficient CNS delivery | High | High | Multiple delivery platforms; intranasal route |
| Off-target microRNA effects | Medium | Medium | Careful ASO design; control sequences |
| Lack of efficacy | Medium | High | Multiple targets; biomarker-driven patient selection |
| Manufacturing challenges | Medium | Medium | Early manufacturing engagement |

Cross-Linking

[RNA Splicing](/mechanisms/rna-splicing)
[MicroRNA Function](/mechanisms/microrna-dysfunction)
[Synaptic Plasticity](/mechanisms/synaptic-plasticity)

[CDR1as](/genes/cdR1as) (circular RNA)
[miR-7](/genes/mir7)
[SAMD4A](/genes/samd4a)

[ASO-Mediated Gene Therapy](/therapeutics/antisense-oligonucleotide-therapy)
[CRISPR Epigenetic Silencing](/ideas/payload-crispri-snca-silencing)
[mRNA-encoded Intrabody Therapy](/ideas/payload-mrna-intrabody-synuclein)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10/10 | circRNA therapeutics are highly novel; very early stage for neurodegeneration |
| Mechanistic Rationale | 6/10/10 | circRNAs regulate gene expression; mechanism of therapeutic restoration unclear |
| Addresses Root Cause | 6/10/10 | Addresses regulatory dysfunction; indirect effect on core pathology |
| Delivery Feasibility | 4/10/10 | RNA delivery to brain extremely challenging; AAV or lipid nanoparticles needed |
| Safety Plausibility | 6/10/10 | Gene therapy safety profile; off-target effects possible |
| Combinability | 5/10/10 | Novel mechanism; limited combination data available |
| Biomarker Availability | 5/10/10 | circRNA detection in CSF possible but not validated for therapy monitoring |
| De-risking Path | 4/10/10 | Very early stage; significant research needed before clinical translation |
| Multi-disease Potential | 6/10/10 | Potential for multiple diseases; mechanism not disease-specific |
| Patient Impact | 6/10/10 | High long-term potential; currently speculative |
| Total | 57/100 | |

Cross-Links

[Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Aging](/diseases/aging)](/diseases/parkinsons-disease)
Mechanisms: [RNA Splicing](/mechanisms/rna-splicing), [Gene Expression Regulation](/mechanisms/gene-expression-regulation), [MicroRNA Function](/mechanisms/microrna-function), [Synaptic Plasticity](/mechanisms/synaptic-plasticity), [Protein Quality Control](/mechanisms/protein-quality-control-network)mechanisms/protein-quality-control-network), [Epigenetics](/mechanisms/epigenetics)
Proteins: [CDR1as](/entities/cdr1as), [MiR-7](/entities/mir-7), [SAMD4A](/entities/samd4a), [ADARB1](/genes/adarb1), [FUS](/entities/fus), [TDP-43](/proteins/tdp-43)
[Cell Types: [Neurons](/entities/neurons), [Synapses](/entities/synapses), [Microglia](/entities/microglia), [Astrocytes](/entities/astrocytes)](/cell-types/microglia)
Treatments: [ASO Therapy](/therapeutics/aso-therapy), [Gene Therapy](/therapeutics/gene-therapy), [CRISPR Therapy](/therapeutics/crispr-therapy), [RNA-Targeting Therapy](/therapeutics/rna-targeting-therapy)

References

[Hanan et al., circRNAs in neurodegeneration (2022) (2022)](https://doi.org/10.1038/s41582-022-00650-9)

[Kumar et al., Circular RNAs as therapeutic targets (2023) (2023)](https://doi.org/10.1038/s41573-023-00256-8)

[Kristensen et al., The biogenesis, biology, and function of circRNAs (2022) (2022)](https://doi.org/10.1038/s41586-022-04589-1)

[Hansen et al., CDR1as functions as a miR-7 sponge (2013) (2013)](https://doi.org/10.1038/nature11993)

[Dube et al., circSAMD4A in synaptic function (2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.008)

[Zhang et al., circH1PRX in AD (2021) (2021)](https://doi.org/10.1186/s13148-021-01136-5)

[Jin et al., circTLK2 in PD (2022) (2022)](https://doi.org/10.1002/mds.29132)

[Ahmad et al., circRNA decline in neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.tins.2023.04.012)

[Rigo et al., ASO-mediated splicing modulation (2014) (2014)](https://doi.org/10.1016/j.tips.2014.04.003)

[Wesselhoeft et al., Engineering circular RNA (2019) (2019)](https://doi.org/10.1038/s41587-019-0068-4)

[Ruan et al., CRISPR activation of circRNA (2021) (2021)](https://doi.org/10.1038/s41587-021-00924-5)

[Piwecka et al., Loss of CDR1as leads to dysfunction (2017) (2017)](https://doi.org/10.1126/science.aam8526)

[Zhang et al., AAV-CDR1as improves cognition (2022) (2022)](https://doi.org/10.1093/brain/awab456)

[Lukiw et al., CDR1as decline in AD (2018) (2018)](https://doi.org/10.1016/j.jad.2018.02.045)

[Saugstad et al., miR-7 in neurodegeneration (2022) (2022)](https://doi.org/10.1002/alz.12589)

[Dube et al., circSAMD4A neuronal function (2020) (2020)](https://doi.org/10.1093/hmg/ddz201)

[Chen et al., circTLK2 dopaminergic toxicity (2023) (2023)](https://doi.org/10.1002/mds.29456)

[Grasso et al., circRNA and cognitive aging (2021) (2021)](https://doi.org/10.1038/s43587-021-00089-3)

[Bhamja et al., circRNA biomarkers in neurodegeneration (2022) (2022)](https://doi.org/10.1186/s40035-022-00312-2)

[Siegel et al., CDR1as in CSF (2021) (2021)](https://doi.org/10.1111/jcmm.16123)

[Hanan et al., Blood circRNA signatures for AD/PD (2020) (2020)](https://doi.org/10.1186/s40035-020-00211-2)

📖 View canonical wiki page →

Related Entities

ideas-circrna-dysfunction-restoration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-circrna-dysfunction-restoration
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-07599e7b4881
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-circrna-dysfunction-restoration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

47

Outgoing

49

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

circRNA Dysfunction Restoration Therapy

Overview

Overview

Mechanistic Rationale

The circRNA Biology

Why circRNA Restoration?

Therapeutic Approaches

Target Selection Priority

Evidence Base

Preclinical Evidence

CDR1as

Other circRNAs

Clinical Evidence

circRNA as Biomarkers

Implementation Roadmap

Preclinical Development (Years 1-4)

Clinical Development (Years 5-8)

Commercial Considerations

Actionable Next Steps

Immediate (0-6 months)

Near-term (6-18 months)

Medium-term (1-3 years)

Key Risks

Cross-Linking

See Also

External Links

Rubric Score

Cross-Links

References

💬 Discussion

📗 Cite This Artifact

circRNA Dysfunction Restoration Therapy

Overview

Overview

Mechanistic Rationale

The circRNA Biology

Why circRNA Restoration?

Therapeutic Approaches

Target Selection Priority

Evidence Base

Preclinical Evidence

CDR1as

Other circRNAs

Clinical Evidence

circRNA as Biomarkers

Implementation Roadmap

Preclinical Development (Years 1-4)

Clinical Development (Years 5-8)

Commercial Considerations

Actionable Next Steps

Immediate (0-6 months)

Near-term (6-18 months)

Medium-term (1-3 years)

Key Risks

Cross-Linking

Related Mechanisms

Related Genes/Proteins

Related Therapies

Related Diseases

See Also

External Links

Rubric Score

Cross-Links

References

💬 Discussion